Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)
A legfontosabb adatok
- Ki végzi
- Seoul National University Hospital
- Hol
- Seoul (Dél-Korea)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 4. fázis
- Résztvevők
- 632 fő, tervezett
- Kezdés
- 2026. aug. 15.
- Várható befejezés
- 2030. jún. 15.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Angiotensin Receptor Blocker (ARB)
- A regiszteradat frissítve
- 2026. július 29.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with severe, symptom-causing aortic stenosis and a thickened heart muscle who had a successful TAVR in the last 30 days. People get an ARB medicine or no ARB.
- Életkor
- 40 years or older
- Nem
- Male or female
- A betegség stádiuma
- Symptomatic severe aortic stenosis (valve area ≤1.0 cm², valve area index ≤0.6 cm²/m², mean gradient ≥40 mmHg, or peak velocity ≥4.0 m/sec). Left ventricular hypertrophy (mass index >115 g/m² in men, >95 g/m² in women). Heart pumping strength (LVEF) >40% before TAVR.
- Korábbi kezelés
- Must have had a successful TAVR (native-valve or valve-in-valve) within the prior 30 days, meeting all VARC-3 success criteria.
A részvétel fő kizáró okai
- Low blood pressure (systolic <90 mmHg) or need for continuous IV drugs to support blood pressure
- High blood potassium (>5.5 mmol/L)
- Allergy or past intolerance to angiotensin receptor blockers
- Pregnancy, breastfeeding, or planning a pregnancy
- eGFR <30 mL/min/1.73 m^2 or on kidney replacement therapy; acute coronary syndrome in the past 1 year; life expectancy under 2 years
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female aged 40 years or older
- Symptomatic severe aortic stenosis (AS) with left ventricular hypertrophy (LVH) who successfully underwent transcatheter aortic valve replacement (TAVR) within the prior 30 days, including native-valve or valve-in-valve TAVR; Severe AS defined by at least one of the following: aortic valve area ≤1.0 cm²; aortic valve area index ≤0.6 cm²/m²; mean pressure gradient ≥40 mmHg; or maximal aortic valve velocity ≥4.0 m/sec; LVH defined as left ventricular mass index >115 g/m² in men or >95 g/m² in women
- Successful TAVR (technical success) meeting all VARC-3 criteria: survival; successful access, delivery, and retrieval of the device; correct positioning of a single prosthetic valve in the proper anatomic location; no additional surgery or procedure related to the device (excluding permanent pacemaker implantation) or to major vascular, access-site, or cardiac structural complications; and intended prosthetic valve performance (mean gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation)
- Left ventricular ejection fraction (LVEF) >40% before TAVR
- Provided written informed consent to participate, either voluntarily or through a legal representative
Ki nem vehet részt
- Allergy, hypersensitivity, or prior intolerance to angiotensin receptor blockers
- Acute coronary syndrome diagnosed within the past 1 year
- Any other medical condition that, in the investigator's judgment, makes participation in the trial inappropriate
- Hyperkalemia (serum potassium >5.5 mmol/L)
- Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m\^2 by the CKD-EPI equation, or currently undergoing renal replacement therapy
- Hypotension (systolic blood pressure <90 mmHg) or hemodynamic instability defined as a need for continuous intravenous vasopressor support at screening
- Bilateral renal artery stenosis without stent placement
- Pregnancy, breastfeeding, or planning to become pregnant
- Estimated life expectancy of less than 2 years
Helyszínek itt: Dél-Korea
- Seoul National University HospitalSeoul, Dél-KoreaContact: Jung-Kyu Han, MD, PhDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a multicenter, prospective, open-label, randomized, investigator-initiated trial evaluating whether angiotensin receptor blocker (ARB) therapy improves clinical outcomes in patients with severe aortic stenosis (AS) and left ventricular hypertrophy (LVH) who have undergone transcatheter aortic valve replacement (TAVR).
A teljes eredeti leírásKevesebb
Severe AS imposes chronic pressure overload on the left ventricle, leading to LVH as a compensatory response. While initially adaptive, sustained LVH promotes myocardial fibrosis, reduced ventricular compliance, and impaired cardiac function. LVH that persists after valve replacement is associated with increased morbidity and mortality, including a higher risk of heart failure. Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEi) or ARBs has been proposed as a strategy to attenuate adverse left ventricular remodeling after valve replacement by inhibiting angiotensin II-mediated hypertrophic and fibrotic signaling. However, evidence in TAVR patients with LVH remains limited, and a small randomized trial of an ACEi reported drug discontinuation in approximately 10% of patients due to dry cough. The ARBITAR trial therefore evaluates the clinical efficacy of an ARB in this population.
A total of 632 patients with symptomatic severe AS and LVH who have successfully undergone TAVR within the prior 30 days will be randomized 1:1 to receive an ARB (experimental group) or no ARB (control group), stratified by site and sex. Assigned treatment is continued for up to 24 months, with follow-up visits at 1, 6, 12, and 24 months. In the experimental group, the ARB (candesartan, losartan, or valsartan) is up-titrated toward a target dose. ACE inhibitors, direct renin inhibitors, and angiotensin receptor/neprilysin inhibitors are prohibited in both groups.
The primary endpoint is the composite of all-cause death or admission for heart failure over 2 years. Secondary endpoints include the individual components of the primary endpoint and other clinical events, as well as echocardiographic measures, NT-proBNP, NYHA functional class, and KCCQ-12 score. The primary analysis follows the intention-to-treat principle.
A vizsgálat 2 csoportja
- Angiotensin Receptor Blocker (ARB) GroupA vizsgált kezelés
Participants in this group receive an angiotensin receptor blocker (candesartan, losartan, or valsartan) in addition to standard care after TAVR. As a principle, the ARB is up-titrated toward the target daily dose, but it may be initiated at a lower starting dose based on clinical need. Assigned treatment is continued for up to 24 months. ACE inhibitors, direct renin inhibitors, and angiotensin receptor/neprilysin inhibitors are prohibited.
Kezelés: Angiotensin Receptor Blocker (ARB)
- Control (No ARB) GroupNincs vizsgálati kezelés, összehasonlításként
Participants in this group receive standard care after TAVR without any angiotensin receptor blocker during the study period. ACE inhibitors, direct renin inhibitors, and angiotensin receptor/neprilysin inhibitors are also prohibited in this group. Participants are followed for up to 24 months.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Angiotensin Receptor Blockade In Patients After Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR) Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. július 29.